Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelquistinel in Major Depressive Disorder
NCT07115329Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing zelquisitinel (GATE-251) with Placebo (2 arms). Primary endpoint: Hamilton Depression Rating Scale-17 at 6 weeks. Started Jan 2026; status: recruiting.
02
Drugs
zelquistinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07115329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115329.